Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy: Double-blind study☆
References (17)
Methotrexate therapy in rheumatoid arthritis: 15 years experience
Am J Med
(1983)- et al.
Low-dose pulse methotrexate treatment of rheumatoid arthritis
Am J Med
(1985) - et al.
Efficacy of low-dose methotrexate in rheumatoid arthritis
N Engl J Med
(1985) - et al.
Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
Arthritis Rheum
(1985) - et al.
Weekly pulse methotrexate in rheumatoid arthritis
Ann Intern Med
(1985) - et al.
The safety and efficacy of methotrexate in the long-term therapy of rheumatoid arthritis
Arthritis Rheum
(1986) - et al.
Psoriasis-liver-methotrexate interactions
Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics
Acta Pathol Microbiol Scand
(1977)
Cited by (89)
Specific in vitro binding of a new <sup>99m</sup>Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils
2015, International Journal of PharmaceuticsCitation Excerpt :The immunostimulating activity of [Re]ProTα-D1 was assessed in comparison with intact ProTα, the synthetic fragments ProTα[100-109], ProTα[100-105], ProTα[1-14],Tα1, ProTα[51-89] and ProTα[50-89]N50 W, the [Re]complex of a derivative encompassing the N-terminal fragment [1-14] of ProTα/Tα1 previously developed by our group ([Re]ProTα-D2), the positive-control peptide fMLP (Wittmann et al., 2002), the negative-control peptide NCP1a, and the negative-control [Re]complex, [Re]NCP1b. Two in vitro bioassays measuring superoxide anion production i.e., the nitroblue tetrazolium (NBT) reduction assay (Kremer et al., 1987) and reactive oxygen species (ROS) by flow cytometry (FC) using CM-H2DCFDA (Saito et al., 2013) were performed. Moreover, the zymosan particle incorporation assay was used to evaluate phagocytosis (Carvalho et al., 2000) in the presence of some of the compounds.
Methotrexate
2015, Rheumatology: Sixth EditionRecommendations of the French Society of Rheumatology for the management of rheumatoid arthritis
2014, Revue du Rhumatisme (Edition Francaise)Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis
2014, Joint Bone SpineCitation Excerpt :Again, dosage reduction seems preferable over the abrupt discontinuation of methotrexate or any other synthetic DMARD. Abrupt discontinuation is associated with a high relapse rate of about 70%, i.e., 2-fold that seen with continued treatment [113–115], and the reintroduction of the synthetic DMARD only inconsistently restores the previous status [116]. It would seem important to define a sustained remission using a strict composite criterion including the absence of synovitis, systemic inflammation, and structural disease progression [38,108–110].
Rheumatoid Arthritis
2010, Current Clinical Medicine: Expert Consult Premium Edition - Enhanced Online Features and PrintCan biomarkers predict successful tapering of conventional disease-modifying therapy in rheumatoid arthritis patients in stable remission?
2023, Clinical and Experimental Rheumatology
- ☆
This work was supported in part by National Institute of Health Grant 5M01-RR-00749-13 and a grant from Lederle Laboratories.